- Home
- AARD vs MRLN Comparison
AARD vs MRLN Comparison
Compare AARD & MRLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AARD | MRLN |
|---|---|---|
| Founded | 2017 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 97.4M | 86.8M |
| IPO Year | 2025 | 2024 |
Fundamental Metrics
Financial Performance| Metric | AARD | MRLN |
|---|---|---|
| Price | $1.23 | $0.94 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 6 |
| Target Price | $7.50 | ★ $7.92 |
| AVG Volume (30 Days) | 1.2M | ★ 2.6M |
| Earning Date | 11-16-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 43.11 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $9.23 |
| Revenue Next Year | N/A | $153.29 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.93 | $0.82 |
| 52 Week High | $16.60 | $17.00 |
Technical Indicators
Market Signals| Indicator | AARD | MRLN |
|---|---|---|
| Relative Strength Index (RSI) | 23.87 | 32.11 |
| Support Level | $0.93 | $0.82 |
| Resistance Level | $5.88 | $3.45 |
| Average True Range (ATR) | 0.44 | 0.12 |
| MACD | -0.20 | 0.06 |
| Stochastic Oscillator | 9.42 | 27.96 |
Price Performance
Historical ComparisonAbout AARD Aardvark Therapeutics Inc.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
About MRLN Merlin Inc. Common Stock
Merlin Inc develops software that fulfills the functions of a human pilot in self-flying aircraft to enable both reduced crew and unmanned flight. This technology is designed to be scalable and adaptable across different aircraft types for a growing range of aircraft platforms. The company's aircraft-agnostic, AI-powered software is purpose-built for military and civil programs, and is powering an expanding range of missions and aircraft, through hundreds of autonomous flights from test facilities across the globe. It operates as a single operating and reportable segment.